The Horizon trial will see if an investigational vaccine (a vaccine that is being studied) may help reduce multiple sclerosis disease activity. The vaccine is for Epstein-Barr virus, which increases the risk for MS and may make symptoms worse. Almost all people with MS have EBV, and research shows EBV as a contributing cause of MS. Researchers are working to better understand the relationship between EBV and MS.
The trial will see if an investigational vaccine may be able to prevent EBV from activating and spreading to other cells in the body in people aged 18-55 years of age. The investigational vaccine will be compared to a placebo jab. The placebo jab will contain an inactive substance that will have no effect on your own health.
